Clinical Trial Update: Metronomic Docetaxel and Bevacizumab in Patients With Small Cell Lung Cancer [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial of metronomic docetaxel and bevacizumab in small cell lung cancer has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Small Cell Lung Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)
• DOCETAXEL (DOCETAXEL)

Snippet

Sponsor: University Hospital of Crete | Conditions: Small Cell Lung Cancer | Phase 2 | Status: WITHDRAWN